Our preclinical investigation revealed that high PRDM15 expression in cancer was significantly associated with poor tumor regression after neoadjuvant chemoradiotherapy; Moreover, PRDM15 upregulation predicted an inferior prognosis in locally advanced rectal cancer patients, who had received neoadjuvant chemoradiotherapy. The gene discussed is PRDM15; the disease is cancer.